Cardinal Health (CAH) 10-Q 5 Nov 14 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'cah	'
Entity Registrant Name	'CARDINAL HEALTH INC	'
Entity Central Index Key	'0000721371	'
Current Fiscal Year End Date	'--06-30	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	330,961,546

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Earnings (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'
Revenue	$24,070	$24,523
Cost of products sold	22,729	23,259
Gross margin	1,341	1,264
Operating expenses:	'	'
Distribution, selling, general and administrative expenses	775	732
Restructuring and employee severance	19	11
Amortization and other acquisition-related costs	53	49
Impairments and loss on disposal of assets	0	0
Litigation (recoveries)/charges, net	28	1
Operating earnings	466	471
Other income, net	-3	-4
Interest expense, net	34	33
Earnings before income taxes and discontinued operations	435	442
Provision for income taxes	169	102
Earnings from continuing operations	266	340
Loss from discontinued operations, net of tax	0	-1
Net earnings	$266	$339
Basic earnings per common share:	'	'
Continuing operations	$0.79	$1
Discontinued operations	$0	$0
Net basic earnings per common share	$0.79	$1
Diluted earnings per common share:	'	'
Continuing operations	$0.78	$0.99
Discontinued operations	$0	$0
Net diluted earnings per common share	$0.78	$0.99
Weighted-average number of common shares outstanding:	'	'
Basic	336	340
Diluted	340	344
Cash dividends declared per common share	$0.34	$0.30

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Net earnings	$266	$339
Other comprehensive income/(loss):	'	'
Net change in foreign currency translation adjustments	-24	24
Net unrealized gain/(loss) on derivative instruments, net of tax	0	0
Total other comprehensive income/(loss), net of tax	-24	24
Total comprehensive income	$242	$363

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Current assets:	'	'
Cash and equivalents	$2,469	$2,865
Trade receivables, net	5,662	5,380
Inventories, net	8,069	8,266
Prepaid expenses and other	1,338	1,428
Total current assets	17,538	17,939
Property and equipment, net	1,434	1,459
Goodwill and other intangibles, net	5,923	5,870
Other assets	816	765
Total assets	25,711	26,033
Current liabilities:	'	'
Accounts payable	11,995	12,149
Current portion of long-term obligations and other short-term borrowings	843	801
Other accrued liabilities	2,058	2,165
Total current liabilities	14,896	15,115
Long-term obligations, less current portion	3,164	3,171
Deferred income taxes and other liabilities	1,395	1,346
Preferred shares, without par value:	'	'
Authorized-500 thousand shares, Issued-none	0	0
Common shares, without par value:	'	'
Authorized-755 million shares, Issued-364 million shares at September 30, 2014 and June 30, 2014	2,948	2,980
Retained earnings	4,925	4,774
Common shares in treasury, at cost: 30 million shares and 27 million shares at September 30, 2014 and June 30, 2014, respectively	-1,663	-1,423
Accumulated other comprehensive income	46	70
Total shareholders' equity	6,256	6,401
Total liabilities and shareholders' equity	$25,711	$26,033

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Preferred shares, No Par Value	'	'
Preferred shares, Authorized	0.5	0.5
Preferred shares, Issued	0	0
Common shares, No Par Value	'	'
Common shares, Authorized	755	755
Common shares, Issued	364	364
Common shares in treasury	30	27

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net earnings	$266	$339
Loss from discontinued operations, net of tax	0	1
Earnings from continuing operations	266	340
Adjustments to reconcile earnings from continuing operations to net cash provided by operating activities:	'	'
Depreciation and amortization	108	117
Gain on sale of other investments	-5	0
Share-based compensation	25	24
Provision for bad debts	12	12
Change in operating assets and liabilities, net of effects from acquisitions:	'	'
Decrease/(increase) in trade receivables	-291	1,395
Decrease in inventories	199	1,098
Decrease in accounts payable	-157	-1,852
Other accrued liabilities and operating items, net	-96	-183
Net cash provided by operating activities	61	951
Cash flows from investing activities:	'	'
Acquisition of subsidiaries, net of cash acquired	-61	-25
Additions to property and equipment	-36	-26
Purchase of available-for-sale securities and other investments	-75	0
Proceeds from sale of available-for-sale securities and other investments	91	0
Net cash used in investing activities	-81	-51
Cash flows from financing activities:	'	'
Net change in short-term borrowings	40	20
Net proceeds from issuance of common shares	25	75
Tax proceeds from share-based compensation	38	12
Dividends on common shares	-119	-105
Purchase of treasury shares	-360	-50
Net cash used in financing activities	-376	-48
Net increase/(decrease) in cash and equivalents	-396	852
Cash and equivalents at beginning of period	2,865	1,901
Cash and equivalents at end of period	$2,469	$2,753

Basis_of_Presentation_Summary_

Basis of Presentation, Summary of Significant Accounting Policies and Other	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Summary of Significant Accounting Policies	'
	Basis of Presentation and Summary of Significant Accounting Policies
	Basis of Presentation
	Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. To conform to the current year presentation, certain prior year amounts have been reclassified. References to "we," "our" and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the effective date of the acquisition or up to the date of disposal, respectively.
	Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include all of the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In addition, operating results presented for this fiscal 2015 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2015.
	These condensed consolidated financial statements are unaudited and are presented pursuant to the rules and regulations of the SEC. Accordingly, the condensed consolidated financial statements included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2014 (the "2014 Form 10-K"). In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.
	Recent Financial Accounting Standards
	In August 2014, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to uncertainties about an entity’s ability to continue as a going concern. This guidance requires management to evaluate whether there is substantial doubt about a company’s ability to continue as a going concern. This amendment will be effective for us in the fourth quarter of fiscal 2017, with early adoption permitted. We do not expect the adoption of this guidance to impact our financial statement disclosures.
	In May 2014, the FASB issued amended accounting guidance related to revenue recognition. This guidance is based on the principle that revenue is recognized in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This amendment will be effective for us in the first quarter of fiscal 2018. We are continuing to evaluate the options for adoption and the impact on our financial position and results of operations.
	In July 2013, the FASB issued amended accounting guidance related to the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless certain conditions exists. We adopted this guidance in the first quarter of fiscal 2015. The adoption of this guidance did not impact our financial position or results of operations.
	In March 2013, the FASB issued amended accounting guidance related to a parent company's accounting for the cumulative translation adjustment upon derecognition of certain subsidiaries or group of assets within a foreign entity or of an investment in a foreign entity. The amended guidance requires the release of any cumulative translation adjustment into net income only upon complete or substantially complete liquidation of a controlling interest in a subsidiary or a group of assets within a foreign entity. Also, it requires the release of all or a pro rata portion of the cumulative translation adjustment to net income in the case of sale of an equity method investment that is a foreign entity. We adopted this amended guidance in the first quarter of fiscal 2015. The adoption of this guidance did not impact our financial position or results of operations.

Acquisitions

Acquisitions	3 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions
	While we have completed acquisitions during the three months ended September 30, 2014, the pro forma results of operations and the results of operations for acquired businesses since the acquisition dates have not been separately disclosed because the effects were not significant compared to the consolidated financial statements, individually or in the aggregate.
	AccessClosure
	On May 9, 2014, we completed the acquisition of Access Closure, Inc. ("AccessClosure") for $320 million in an all-cash transaction. We funded the acquisition with cash on hand. The acquisition of AccessClosure, a manufacturer and distributor of extravascular closure devices, expands the Medical segment's portfolio of self-manufactured products. The assessment of fair value for AccessClosure is preliminary and is based on information that was available at the time the condensed consolidated financial statements were prepared.

Restructuring_and_Employee_Sev

Restructuring and Employee Severance	3 Months Ended
	Sep. 30, 2014
Restructuring Charges [Abstract]	'
Restructuring and Employee Severance	'
	Restructuring and Employee Severance
	The following table summarizes restructuring and employee severance costs related to our restructuring activities:
		Three Months Ended September 30
	(in millions)	2014			2013
	Employee-related costs (1)	$	16		$	4
	Facility exit and other costs (2)	3			7
	Total restructuring and employee severance	$	19		$	11
	-1	Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods.
	-2	Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.
	The majority of restructuring costs incurred during the three months ended September 30, 2014 and 2013 related to restructuring activities within our Medical segment.
	The following table summarizes activity related to liabilities associated with restructuring and employee severance:
	(in millions)	Employee-			Facility Exit		Total
		Related Costs			and Other Costs
	Balance at June 30, 2014	$	24		$	—	$	24
	Additions	17			—		17
	Payments and other adjustments	(11		)	—		(11		)
	Balance at September 30, 2014	$	30		$	—	$	30

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	Goodwill
	The following table summarizes the changes in the carrying amount of goodwill, by segment and in total:
	(in millions)	Pharmaceutical		Medical			Total
	Balance at June 30, 2014	$	2,158	$	2,720		$	4,878
	Goodwill acquired, net of purchase price adjustments	6		50			56
	Foreign currency translation adjustments and other	6		(5		)	1
	Balance at September 30, 2014	$	2,170	$	2,765		$	4,935
	Other Intangible Assets
	Other intangible assets are amortized over periods ranging from one to twenty years. The following tables summarize other intangible assets by class at:
		September 30, 2014
	(in millions)	Gross		Accumulated			Net
		Intangible		Amortization			Intangible
	Indefinite-life intangibles:
	Trademarks and other	$	14	$	—		$	14
	Total indefinite-life intangibles	14		—			14
	Definite-life intangibles:
	Customer relationships	1,039		404			635
	Trademarks, trade names and patents	221		74			147
	Developed technology and other	296		104			192
	Total definite-life intangibles	1,556		582			974
	Total other intangible assets	$	1,570	$	582		$	988
		June 30, 2014
	(in millions)	Gross		Accumulated			Net
		Intangible		Amortization			Intangible
	Indefinite-life intangibles:
	Trademarks and other	$	14	$	—		$	14
	Total indefinite-life intangibles	14		—			14
	Definite-life intangibles:
	Customer relationships	1,043		388			655
	Trademarks, trade names and patents	213		69			144
	Developed technology and other	258		79			179
	Total definite-life intangibles	1,514		536			978
	Total other intangible assets	$	1,528	$	536		$	992
	Total amortization of intangible assets was $45 million and $46 million for the three months ended September 30, 2014 and 2013, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2015 through 2019 is as follows: $139 million, $174 million, $165 million, $123 million and $77 million.

AvailableforSale_Securities

Available-for-Sale Securities	3 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Available-for-Sale Securities Disclosure	'
	Available-for-Sale Securities
	We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. We held the following investments in marketable securities at fair value at:
	(in millions)	September 30, 2014		June 30, 2014
	Current available-for-sale securities:
	Commercial paper	$	15	$	4
	Treasury bills	3		85
	International bonds	1		1
	Corporate bonds	4		3
	U.S. agency mortgage-backed securities	2		—
	Total current available-for-sale securities	25		93
	Long-term available-for-sale securities:
	Corporate bonds	10		5
	U.S. agency bonds	43		2
	U.S. agency mortgage-backed securities	13		—
	Total long-term available-for-sale securities	66		7
	Total available-for-sale securities	$	91	$	100
	Gross unrealized gains and losses were immaterial at September 30, 2014. During the three months ended September 30, 2014, gross realized gains and losses were immaterial and we did not recognize any other-than-temporary impairments. At September 30, 2014 the weighted-average effective maturity of our current and long-term investments was approximately 5 months and 17 months, respectively.

Income_Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Generally, fluctuations in our provision for income taxes as a percentage of pretax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
	During the three months ended September 30, 2014, the effective tax rate of 38.9 percent was unfavorably impacted by 2.6 percentage points ($11 million) due to the remeasurement of unrecognized tax benefits and 2.4 percentage points ($10 million) due to nondeductibility of litigation charges, partially offset by 3.3 percentage points ($14 million) due to adjusting deferred tax assets and related valuation allowances for the impact of Puerto Rico tax law changes enacted during the quarter.
	During the three months ended September 30, 2013, the effective tax rate of 23.2 percent was impacted by net favorable discrete items of $61 million, which reduced the rate by 13.7 percentage points. The discrete items include the favorable impact of the settlement of federal and state tax controversies ($63 million).
	We had $524 million and $510 million of unrecognized tax benefits at September 30, 2014 and June 30, 2014, respectively. The September 30, 2014 and June 30, 2014 balances include $331 million and $322 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate. The remaining unrecognized tax benefits relate to tax positions for which ultimate deductibility is highly certain but for which there is uncertainty as to the timing of such deductibility. Recognition of these tax benefits would not affect our effective tax rate. We include the full amount of unrecognized tax benefits in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
	We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. At September 30, 2014 and June 30, 2014, we had $155 million and $143 million, respectively, accrued for the payment of interest and penalties. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
	It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, including proposed assessments of additional tax, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of applicable statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is a decrease of approximately $45 million to an increase of approximately $20 million, exclusive of penalties and interest.
	We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. We are subject to audit by the IRS for fiscal years 2006 through the current fiscal year. We are generally subject to audit by taxing authorities in various U.S. state and foreign jurisdictions for fiscal years 2003 through the current fiscal year.
	The IRS is currently conducting audits of fiscal years 2006 through 2010, and our transfer pricing arrangements continue to be under consideration as part of these audits. While the IRS has made and could make proposed adjustments to our transfer pricing arrangements or other matters, we are defending our reported tax positions, and have accounted for the unrecognized tax benefits associated with our tax positions.
	We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), under which CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $212 million and $210 million at September 30, 2014 and June 30, 2014, respectively, and is included in other assets in the condensed consolidated balance sheets.

Commitments_Contingent_Liabili

Commitments, Contingent Liabilities and Litigation	3 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments, contingent liabilities and litigation	'
	Commitments, Contingent Liabilities and Litigation
	Commitments
	Joint Venture With CVS Health Corporation
	In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing entity with CVS Health Corporation (“CVS”) with an initial term of 10 years. Both companies have contributed sourcing and supply chain expertise to the 50/50 joint venture and have committed to source generic pharmaceuticals through arrangements negotiated by it. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of both companies, but does not own products or hold inventory on behalf of either company. We are required to pay 39 quarterly payments of $25.6 million to CVS commencing in October 2014 and, only if certain milestones are achieved, to pay additional predetermined amounts to CVS beginning in fiscal 2016. The fixed payments of $25.6 million will be expensed evenly commencing during the second quarter of fiscal 2015. No physical assets were contributed by either company to Red Oak Sourcing, and minimal funding has been provided to capitalize the entity.
	Legal Proceedings
	We become involved from time to time in disputes, litigation and regulatory matters incidental to our business, including governmental investigations and enforcement actions, personal injury claims, employment matters, commercial disputes, intellectual property matters, government contract compliance matters, disputes regarding environmental clean-up costs, claims in connection with acquisitions and divestitures and other matters arising out of the normal conduct of our business. We intend to vigorously defend ourselves in such matters.
	We may be named from time to time in qui tam actions, which are initiated by private third parties purporting to act on behalf of federal or state governments that allege that false claims have been submitted or have been caused to be submitted for payment by the government. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on behalf of the government.
	In addition, we occasionally may suspect that products we manufacture, market or distribute do not meet product specifications, published standards or regulatory requirements. In such circumstances, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales and action by regulators.
	We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
	With respect to the matters described below, we are unable to estimate a range of reasonably possible loss for matters for which there is no accrual or additional loss for matters for which we already have recorded an accrual, since damages or fines have not been specified or the proceedings are at stages where significant uncertainty exists as to legal or factual issues and as to whether such matters will proceed to trial. We do not believe, based on currently available information, that the outcomes of these matters will have a material adverse effect on our financial position, results of operations or cash flows, though the outcome of one or more of these matters could be material to our results of operations for a particular period.
	We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
	We recognize estimated loss contingencies for litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings.
	DEA Investigation and Related Matters
	In February 2012, the U.S. Drug Enforcement Administration (the "DEA") issued an order to show cause and immediate suspension of our Lakeland, Florida distribution center's registration to distribute controlled substances, asserting that we failed to maintain required controls against the diversion of controlled substances. In May 2012, we entered into a settlement agreement with the DEA that resolved the administrative aspects of the DEA's action. The settlement agreement did not foreclose the possibility of the U.S. Department of Justice (the “DOJ”) seeking civil fines in Florida or elsewhere for the conduct covered by the settlement agreement. In that regard, we are continuing to provide information to and engage in discussions with several offices of the DOJ, including preliminary discussions regarding the feasibility of a settlement, and have accrued $27 million for this matter.
	State of West Virginia vs. Cardinal Health, Inc.
	In June 2012, the West Virginia Attorney General filed, and in January 2014 amended, complaints against 13 pharmaceutical wholesale distributors, including us, in the Circuit Court of Boone County, West Virginia alleging, among other things, that the distributors failed to maintain effective controls to guard against diversion of controlled substances in West Virginia, failed to report suspicious orders of controlled substances in accordance with the West Virginia Uniform Controlled Substances Act and were negligent in distributing controlled substances to pharmacies that serve individuals who abuse controlled substances. In addition to injunctive and other equitable relief, the complaints seek monetary damages and the creation of a court-supervised fund, to be financed by the defendants in these actions, for a medical monitoring program focused on prescription drug abuse.
	Federal False Claims Investigation
	As previously disclosed, the DOJ had requested information in connection with an investigation of possible violations of the federal False Claims Act with respect to our Medical segment’s administration of a prime vendor agreement with the federal government. The investigation was prompted by a qui tam action filed under seal by a private third party. In September 2014, the DOJ declined to intervene in the qui tam action.
	FTC Investigation
	The Federal Trade Commission (“FTC”) has been investigating supplier arrangements involving our Nuclear Pharmacy Services division primarily focused on the period between 2003 and 2008, and we have been providing information to and cooperating with the FTC on this matter. We believe that the FTC commissioners are now considering whether or not to take civil action against us.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2014
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	The following tables present the fair values for those assets measured on a recurring basis at:
		September 30, 2014
	(in millions)	Level 1		Level 2		Level 3		Total
	Cash equivalents (1)	$	309	$	—	$	—	$	309
	Forward contracts (2)	—		5		—		5
	Available-for-sale securities (3)	—		91		—		91
	Other investments (4)	108		—		—		108
	Total	$	417	$	96	$	—	$	513
		June 30, 2014
	(in millions)	Level 1		Level 2		Level 3		Total
	Cash equivalents (1)	$	740	$	—	$	—	$	740
	Forward contracts (2)	—		10		—		10
	Available-for-sale securities (3)	—		100		—		100
	Other investments (4)	106		—		—		106
	Total	$	846	$	110	$	—	$	956
	-1	Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.
	-2	The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets.
	-3	We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities.
	-4	The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

Financial_Instruments

Financial Instruments	3 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Financial Instruments and Other Financing Arrangements	'
	Financial Instruments
	We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. Our derivative and hedging programs are consistent with those described in the 2014 Form 10-K.
	During the three months ended September 30, 2014, we entered into forward interest rate swaps with a total notional amount of $50 million to hedge probable, but not firmly committed, future transactions associated with our debt.
	Fair Value of Financial Instruments
	The carrying amounts of cash and equivalents, trade receivables, net, accounts payable and other accrued liabilities at September 30, 2014 and June 30, 2014 approximate fair value due to their short-term maturities.
	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
	(in millions)	September 30,		June 30,
		2014		2014
	Estimated fair value	$	4,122	$	4,115
	Carrying amount	4,007		3,972
	The estimated fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.

Shareholders_Equity

Shareholders' Equity	3 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Shareholders' Equity	'
	Shareholders' Equity
	Share Repurchases
	During the three months ended September 30, 2014, we repurchased 4.8 million common shares having an aggregate cost of $360 million. The average price paid per common share was $74.36.
	During the three months ended September 30, 2013, we repurchased 1.0 million common shares having an aggregate cost of $50 million. The average price paid per common share was $51.65.
	We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
	Accumulated Other Comprehensive Income
	The following table summarizes the changes in the balance of accumulated other comprehensive income by component and in total:
	(in millions)	Foreign			Unrealized		Accumulated Other
		Currency			Gain on		Comprehensive
		Translation			Derivatives,		Income
		Adjustments			net of tax
	Balance at June 30, 2014	$	63		$	7	$	70
	Other comprehensive loss, net of tax before reclassifications	(24		)	—		(24		)
	Amounts reclassified to earnings	—			—		—
	Total other comprehensive loss, net of tax	(24		)	—		(24		)
	Balance at September 30, 2014	$	39		$	7	$	46
	Activity related to realized and unrealized gains and losses on available-for-sale securities as described in Note 5, was immaterial during the three months ended September 30, 2014.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	The following table reconciles the number of common shares used to compute basic and diluted earnings per share:
		Three Months Ended September 30
	(in millions)	2014	2013
	Weighted-average common shares–basic	336	340
	Effect of dilutive securities:
	Employee stock options, restricted share units and performance share units	4	4
	Weighted-average common shares–diluted	340	344
	For both the three months ended September 30, 2014 and 2013, there were one million potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive and therefore were not considered in the calculation of diluted earnings per share.

Segment_Information

Segment Information	3 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	Segment Information
	Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates our performance combined with the nature of the individual business activities.
	The following table presents revenue for each reportable segment and Corporate:
		Three Months Ended September 30
	(in millions)	2014			2013
	Pharmaceutical (1)	$	21,209		$	21,813
	Medical	2,852			2,711
	Total segment revenue	24,061			24,524
	Corporate (2)	9			(1		)
	Total revenue	$	24,070		$	24,523
	-1	Our pharmaceutical distribution contract with Walgreen Co. expired on August 31, 2013.
	-2	Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
	We evaluate segment performance based upon segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment SG&A expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal. Corporate expenses are allocated to the segments based upon headcount, level of benefit provided and other ratable allocation methodologies. Other income, net, interest expense, net and provision for income taxes are not allocated to the segments.
	Restructuring and employee severance, amortization and other acquisition-related costs, impairments and loss on disposal of assets and litigation (recoveries)/charges, net are not allocated to the segments. In addition, certain investment and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. We encourage our segments and corporate functions to identify investment projects that will promote innovation and provide future returns. As approval decisions for such projects are dependent upon executive management, the expenses for such projects are often retained at Corporate. Investment spending within Corporate was $2 million and $3 million for the three months ended September 30, 2014 and 2013, respectively.
	The following table presents segment profit by reportable segment and Corporate:
		Three Months Ended September 30
	(in millions)	2014			2013
	Pharmaceutical	$	451		$	433
	Medical	113			106
	Total segment profit	564			539
	Corporate	(98		)	(68		)
	Total operating earnings	$	466		$	471

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments	'
	Share-Based Compensation
	Share-Based Compensation Plans
	We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
	The following table provides total share-based compensation expense by type of award:
		Three Months Ended September 30
	(in millions)	2014			2013
	Restricted share unit expense	$	16		$	16
	Employee stock option expense	5			5
	Performance share unit expense	4			3
	Total share-based compensation	$	25		$	24
	The total tax benefit related to share-based compensation was $9 million for both the three months ended September 30, 2014 and 2013, respectively.
	Stock Options
	Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for periods ranging from seven to ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.
	The following table summarizes all stock option transactions under the Plans:
	(in millions, except per share amounts)	Stock		Weighted-Average
		Options		Exercise Price per
				Common Share
	Outstanding at June 30, 2014	10		$	39.16
	Granted	1		71.52
	Exercised	(2	)	39.25
	Canceled and forfeited	—		—
	Outstanding at September 30, 2014	9		$	44.16
	Exercisable at September 30, 2014	6		$	36.01
	At September 30, 2014, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $39 million, which is expected to be recognized over a weighted-average period of two years. The following table provides additional data related to stock option activity:
	(in millions, except contractual lives)	September 30, 2014			June 30, 2014
	Aggregate intrinsic value of outstanding options at period end	$	282		$	282
	Aggregate intrinsic value of exercisable options at period end	$	219		$	185
	Weighted-average remaining contractual life of outstanding options (in years)	6			6
	Weighted-average remaining contractual life of exercisable options (in years)	5			4
	Restricted Share Units
	Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
	The following table summarizes all transactions related to restricted share units under the Plans:
	(in millions, except per share amounts)	Restricted Share Units		Weighted-Average
				Grant Date Fair
				Value per Share
	Nonvested at June 30, 2014	3		$	45.65
	Granted	1		71.71
	Vested	(1	)	44.34
	Canceled and forfeited	—		—
	Nonvested at September 30, 2014	3		$	56.48
	At September 30, 2014, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $128 million, which is expected to be recognized over a weighted-average period of two years.
	Performance Share Units
	Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 200 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
	The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
	(in millions, except per share amounts)	Performance		Weighted-Average
		Share Units		Grant Date Fair
				Value per Share
	Nonvested at June 30, 2014	0.9		$	44.41
	Granted	0.2		66.67
	Vested (1)	(0.2	)	41.59
	Canceled and forfeited	—		—
	Nonvested at September 30, 2014	0.9		$	50.51
	-1	Vested based on achievement of 120 percent of the target performance goal.
	At September 30, 2014, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $24 million, which is expected to be recognized over a weighted-average period of two years.

Subsequent_Events_Subsequent_E

Subsequent Events Subsequent Events	3 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	Other Financing Arrangements
	On November 3, 2014, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC ("CHF") through November 3, 2017 and increased the size of the facility from $700 million to $950 million. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated in accordance with GAAP, CHF is a separate legal entity from Cardinal Health and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
	Share Repurchases
	During October 2014, we repurchased 3.1 million common shares having an aggregate cost of $231 million. The average price paid per common share was $74.12.

Basis_of_Presentation_Summary_1

Basis of Presentation, Summary of Significant Accounting Policies and Other (Policies)	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation, Policy	'
	Basis of Presentation
	Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. To conform to the current year presentation, certain prior year amounts have been reclassified. References to "we," "our" and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the effective date of the acquisition or up to the date of disposal, respectively.
	Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include all of the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In addition, operating results presented for this fiscal 2015 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2015.
	These condensed consolidated financial statements are unaudited and are presented pursuant to the rules and regulations of the SEC. Accordingly, the condensed consolidated financial statements included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2014 (the "2014 Form 10-K"). In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.
Recent Financial Accounting Standards, Policy	'
	Recent Financial Accounting Standards
	In August 2014, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to uncertainties about an entity’s ability to continue as a going concern. This guidance requires management to evaluate whether there is substantial doubt about a company’s ability to continue as a going concern. This amendment will be effective for us in the fourth quarter of fiscal 2017, with early adoption permitted. We do not expect the adoption of this guidance to impact our financial statement disclosures.
	In May 2014, the FASB issued amended accounting guidance related to revenue recognition. This guidance is based on the principle that revenue is recognized in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This amendment will be effective for us in the first quarter of fiscal 2018. We are continuing to evaluate the options for adoption and the impact on our financial position and results of operations.
	In July 2013, the FASB issued amended accounting guidance related to the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless certain conditions exists. We adopted this guidance in the first quarter of fiscal 2015. The adoption of this guidance did not impact our financial position or results of operations.
	In March 2013, the FASB issued amended accounting guidance related to a parent company's accounting for the cumulative translation adjustment upon derecognition of certain subsidiaries or group of assets within a foreign entity or of an investment in a foreign entity. The amended guidance requires the release of any cumulative translation adjustment into net income only upon complete or substantially complete liquidation of a controlling interest in a subsidiary or a group of assets within a foreign entity. Also, it requires the release of all or a pro rata portion of the cumulative translation adjustment to net income in the case of sale of an equity method investment that is a foreign entity. We adopted this amended guidance in the first quarter of fiscal 2015. The adoption of this guidance did not impact our financial position or results of operations.

Restructuring_and_Employee_Sev1

Restructuring and Employee Severance (Tables)	3 Months Ended
	Sep. 30, 2014
Restructuring Charges [Abstract]	'
Summary of restructuring and employee severance relating to restructuring activity	'
	The following table summarizes restructuring and employee severance costs related to our restructuring activities:
		Three Months Ended September 30
	(in millions)	2014			2013
	Employee-related costs (1)	$	16		$	4
	Facility exit and other costs (2)	3			7
	Total restructuring and employee severance	$	19		$	11
	-1	Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods.
	-2	Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.
Schedule of activity related to liabilities associated with restructuring and employee severance	'
	The following table summarizes activity related to liabilities associated with restructuring and employee severance:
	(in millions)	Employee-			Facility Exit		Total
		Related Costs			and Other Costs
	Balance at June 30, 2014	$	24		$	—	$	24
	Additions	17			—		17
	Payments and other adjustments	(11		)	—		(11		)
	Balance at September 30, 2014	$	30		$	—	$	30

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill by Reportable Segment	'
	The following table summarizes the changes in the carrying amount of goodwill, by segment and in total:
	(in millions)	Pharmaceutical		Medical			Total
	Balance at June 30, 2014	$	2,158	$	2,720		$	4,878
	Goodwill acquired, net of purchase price adjustments	6		50			56
	Foreign currency translation adjustments and other	6		(5		)	1
	Balance at September 30, 2014	$	2,170	$	2,765		$	4,935
Schedule of Intangible Assets	'
	The following tables summarize other intangible assets by class at:
		September 30, 2014
	(in millions)	Gross		Accumulated			Net
		Intangible		Amortization			Intangible
	Indefinite-life intangibles:
	Trademarks and other	$	14	$	—		$	14
	Total indefinite-life intangibles	14		—			14
	Definite-life intangibles:
	Customer relationships	1,039		404			635
	Trademarks, trade names and patents	221		74			147
	Developed technology and other	296		104			192
	Total definite-life intangibles	1,556		582			974
	Total other intangible assets	$	1,570	$	582		$	988
		June 30, 2014
	(in millions)	Gross		Accumulated			Net
		Intangible		Amortization			Intangible
	Indefinite-life intangibles:
	Trademarks and other	$	14	$	—		$	14
	Total indefinite-life intangibles	14		—			14
	Definite-life intangibles:
	Customer relationships	1,043		388			655
	Trademarks, trade names and patents	213		69			144
	Developed technology and other	258		79			179
	Total definite-life intangibles	1,514		536			978
	Total other intangible assets	$	1,528	$	536		$	992

AvailableforSale_Securities_Ta

Available-for-Sale Securities (Tables)	3 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Available-for-sale Securities	'
	We held the following investments in marketable securities at fair value at:
	(in millions)	September 30, 2014		June 30, 2014
	Current available-for-sale securities:
	Commercial paper	$	15	$	4
	Treasury bills	3		85
	International bonds	1		1
	Corporate bonds	4		3
	U.S. agency mortgage-backed securities	2		—
	Total current available-for-sale securities	25		93
	Long-term available-for-sale securities:
	Corporate bonds	10		5
	U.S. agency bonds	43		2
	U.S. agency mortgage-backed securities	13		—
	Total long-term available-for-sale securities	66		7
	Total available-for-sale securities	$	91	$	100

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2014
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'
	The following tables present the fair values for those assets measured on a recurring basis at:
		September 30, 2014
	(in millions)	Level 1		Level 2		Level 3		Total
	Cash equivalents (1)	$	309	$	—	$	—	$	309
	Forward contracts (2)	—		5		—		5
	Available-for-sale securities (3)	—		91		—		91
	Other investments (4)	108		—		—		108
	Total	$	417	$	96	$	—	$	513
		June 30, 2014
	(in millions)	Level 1		Level 2		Level 3		Total
	Cash equivalents (1)	$	740	$	—	$	—	$	740
	Forward contracts (2)	—		10		—		10
	Available-for-sale securities (3)	—		100		—		100
	Other investments (4)	106		—		—		106
	Total	$	846	$	110	$	—	$	956
	-1	Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.
	-2	The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets.
	-3	We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities.
	-4	The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

Financial_Instruments_Tables

Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Summary of the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts	'
	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
	(in millions)	September 30,		June 30,
		2014		2014
	Estimated fair value	$	4,122	$	4,115
	Carrying amount	4,007		3,972

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Schedule of the changes in the balance of accumulated other comprehensive income by component and in total	'
	The following table summarizes the changes in the balance of accumulated other comprehensive income by component and in total:
	(in millions)	Foreign			Unrealized		Accumulated Other
		Currency			Gain on		Comprehensive
		Translation			Derivatives,		Income
		Adjustments			net of tax
	Balance at June 30, 2014	$	63		$	7	$	70
	Other comprehensive loss, net of tax before reclassifications	(24		)	—		(24		)
	Amounts reclassified to earnings	—			—		—
	Total other comprehensive loss, net of tax	(24		)	—		(24		)
	Balance at September 30, 2014	$	39		$	7	$	46

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Reconciliation of common shares used to compute basic and diluted earnings per share	'
	The following table reconciles the number of common shares used to compute basic and diluted earnings per share:
		Three Months Ended September 30
	(in millions)	2014	2013
	Weighted-average common shares–basic	336	340
	Effect of dilutive securities:
	Employee stock options, restricted share units and performance share units	4	4
	Weighted-average common shares–diluted	340	344

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Revenue by Reportable Segment	'
	The following table presents revenue for each reportable segment and Corporate:
		Three Months Ended September 30
	(in millions)	2014			2013
	Pharmaceutical (1)	$	21,209		$	21,813
	Medical	2,852			2,711
	Total segment revenue	24,061			24,524
	Corporate (2)	9			(1		)
	Total revenue	$	24,070		$	24,523
	-1	Our pharmaceutical distribution contract with Walgreen Co. expired on August 31, 2013.
	-2	Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment	'
	The following table presents segment profit by reportable segment and Corporate:
		Three Months Ended September 30
	(in millions)	2014			2013
	Pharmaceutical	$	451		$	433
	Medical	113			106
	Total segment profit	564			539
	Corporate	(98		)	(68		)
	Total operating earnings	$	466		$	471

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of total share-based compensation expense by type of award	'
	The following table provides total share-based compensation expense by type of award:
		Three Months Ended September 30
	(in millions)	2014			2013
	Restricted share unit expense	$	16		$	16
	Employee stock option expense	5			5
	Performance share unit expense	4			3
	Total share-based compensation	$	25		$	24
Schedule of all stock option transactions under the Plans	'
	The following table summarizes all stock option transactions under the Plans:
	(in millions, except per share amounts)	Stock		Weighted-Average
		Options		Exercise Price per
				Common Share
	Outstanding at June 30, 2014	10		$	39.16
	Granted	1		71.52
	Exercised	(2	)	39.25
	Canceled and forfeited	—		—
	Outstanding at September 30, 2014	9		$	44.16
	Exercisable at September 30, 2014	6		$	36.01
Schedule of additional data related to stock option activity	'
	The following table provides additional data related to stock option activity:
	(in millions, except contractual lives)	September 30, 2014			June 30, 2014
	Aggregate intrinsic value of outstanding options at period end	$	282		$	282
	Aggregate intrinsic value of exercisable options at period end	$	219		$	185
	Weighted-average remaining contractual life of outstanding options (in years)	6			6
	Weighted-average remaining contractual life of exercisable options (in years)	5			4
Schedule of all transactions related to restricted share units under the Plans	'
	The following table summarizes all transactions related to restricted share units under the Plans:
	(in millions, except per share amounts)	Restricted Share Units		Weighted-Average
				Grant Date Fair
				Value per Share
	Nonvested at June 30, 2014	3		$	45.65
	Granted	1		71.71
	Vested	(1	)	44.34
	Canceled and forfeited	—		—
	Nonvested at September 30, 2014	3		$	56.48
Schedule of all transactions related to performance share units under the Plans	'
	The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
	(in millions, except per share amounts)	Performance		Weighted-Average
		Share Units		Grant Date Fair
				Value per Share
	Nonvested at June 30, 2014	0.9		$	44.41
	Granted	0.2		66.67
	Vested (1)	(0.2	)	41.59
	Canceled and forfeited	—		—
	Nonvested at September 30, 2014	0.9		$	50.51
	-1	Vested based on achievement of 120 percent of the target performance goal.

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details) (USD $)	3 Months Ended		0 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	9-May-14
			AccessClosure
Business Acquisition	'	'	'
Business Acquisition, Effective Date of Acquisition	'	'	9-May-14
Payments to Acquire Businesses, Net of Cash Acquired	$61	$25	$320

Restructuring_and_Employee_Sev2

Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013
Restructuring Charges [Abstract]	'		'
Employee-related costs	$16	[1]	$4	[1]
Facility exit and other costs	3	[2]	7	[2]
Total restructuring and employee severance	$19		$11
[1]	Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods.
[2]	Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.

Restructuring_and_Employee_Sev3

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Employee-Related Costs	'
Restructuring Reserve	'
Beginning Balance	$24
Additions to restructuring reserve	17
Payments and other adjustments	-11
Ending Balance	30
Facility Exit and Other Costs	'
Restructuring Reserve	'
Beginning Balance	0
Additions to restructuring reserve	0
Payments and other adjustments	0
Ending Balance	0
Total	'
Restructuring Reserve	'
Beginning Balance	24
Additions to restructuring reserve	17
Payments and other adjustments	-11
Ending Balance	$30

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Goodwill and Intangible Assets	'	'
Amortization of Intangible Assets	$45	$46
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	139	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	174	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	165	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four	123	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$77	'
Minimum	'	'
Goodwill and Intangible Assets	'	'
Finite-Lived Intangible Asset, Useful Life	'1 year	'
Maximum	'	'
Goodwill and Intangible Assets	'	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Goodwill	'
Beginning Balance	$4,878
Goodwill acquired, net of purchase price adjustments	56
Foreign currency translation adjustments and other	1
Ending Balance	4,935
Pharmaceutical	'
Goodwill	'
Beginning Balance	2,158
Goodwill acquired, net of purchase price adjustments	6
Foreign currency translation adjustments and other	6
Ending Balance	2,170
Medical	'
Goodwill	'
Beginning Balance	2,720
Goodwill acquired, net of purchase price adjustments	50
Foreign currency translation adjustments and other	-5
Ending Balance	$2,765

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Indefinite-life intangibles:	'	'
Indefinite-Lived Intangible Assets, Gross	$14	$14
Indefinite-Lived Intangible Assets, Accumulated Amortization	0	0
Indefinite-Lived Intangible Assets (Excluding Goodwill)	14	14
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	1,556	1,514
Finite-Lived Intangible Assets, Accumulated Amortization	582	536
Finite-Lived Intangible Assets, Net	974	978
Total Intangibles, Gross	1,570	1,528
Total Intangibles, Accumulated Amortization	582	536
Intangible Assets, Net (Excluding Goodwill)	988	992
Customer relationships	'	'
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	1,039	1,043
Finite-Lived Intangible Assets, Accumulated Amortization	404	388
Finite-Lived Intangible Assets, Net	635	655
Trademarks, trade names and patents	'	'
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	221	213
Finite-Lived Intangible Assets, Accumulated Amortization	74	69
Finite-Lived Intangible Assets, Net	147	144
Developed technology and other	'	'
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	296	258
Finite-Lived Intangible Assets, Accumulated Amortization	104	79
Finite-Lived Intangible Assets, Net	192	179
Trademarks and other	'	'
Indefinite-life intangibles:	'	'
Indefinite-Lived Intangible Assets, Gross	14	14
Indefinite-Lived Intangible Assets, Accumulated Amortization	0	0
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$14	$14

AvailableforSale_Securities_Na

Available-for-Sale Securities (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Schedule of Available-for-sale Securities [Line Items]	'
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	$0
Short Term	'
Schedule of Available-for-sale Securities [Line Items]	'
Weighted average effective maturity	'5 months
Long Term	'
Schedule of Available-for-sale Securities [Line Items]	'
Weighted average effective maturity	'17 months

AvailableforSale_Securities_Sc

Available-for-Sale Securities (Schedule of Available-for-Sale Securities) (Details) (USD $)	Sep. 30, 2014		Jun. 30, 2014
In Millions, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale Securities	$91	[1]	$100	[1]
Available-for-sale Securities, Current	25		93
Available-for-sale Securities, Noncurrent	66		7
Commercial Paper	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale Securities, Current	15		4
Treasury bills	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale Securities, Current	3		85
International bonds	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale Securities, Current	1		1
Corporate bonds	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale Securities, Current	4		3
Available-for-sale Securities, Noncurrent	10		5
U.S. agency bonds	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale Securities, Noncurrent	43		2
U.S. agency mortgage-backed securities	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale Securities, Current	2		0
Available-for-sale Securities, Noncurrent	$13		$0
[1]	We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities.

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
Income Taxes	'	'	'
Effective Income Tax Rate, Continuing Operations	38.90%	23.20%	'
Unfavorable/(favorable) impact due to remeasurement of unrecognized tax benefits, Percent	2.60%	'	'
Unfavorable/(favorable) impact due to remeasurement of unrecognized tax benefits, Amount	$11	'	'
Unfavorable/(favorable) impact of nondeductible litigation expense, Percent	2.40%	'	'
Unfavorable/(favorable) impact of nondeductible litigation expense, Amount	10	'	'
Unfavorable/(favorable) impact of Puerto Rico tax law changes, Percent	3.30%	'	'
Unfavorable/(favorable) impact of Puerto Rico tax law changes, Amount	14	'	'
Net Unfavorable/(Favorable) Discrete Items, Amount	'	61	'
Net Unfavorable/(Favorable) Discrete Items, Percent	'	13.70%	'
Unfavorable/(favorable) impact of settlements of federal and state tax controversies, settlements and unusual provisions, Amount	'	63	'
Unrecognized tax benefits	524	'	510
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	331	'	322
Significant Increase/(Decrease) in Unrecognized Tax Benefits is Reasonably Possible, Estimated Range of Change, Lower Bound	-45	'	'
Significant Increase/(Decrease) in Unrecognized Tax Benefits is Reasonably Possible, Estimated Range of Change, Upper Bound	20	'	'
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	155	'	143
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority	$212	'	$210
Federal | Minimum	'	'	'
Income Taxes	'	'	'
Tax years open for examination	'2006	'	'
Tax years under examination	'2006	'	'
Federal | Maximum	'	'	'
Income Taxes	'	'	'
Tax years open for examination	'2014	'	'
Tax years under examination	'2010	'	'
State and Foreign Jurisdiction | Minimum	'	'	'
Income Taxes	'	'	'
Tax years open for examination	'2003	'	'
State and Foreign Jurisdiction | Maximum	'	'	'
Income Taxes	'	'	'
Tax years open for examination	'2014	'	'

Commitments_Contingent_Liabili1

Commitments, Contingent Liabilities and Litigation (Narrative) (Details) (USD $)	3 Months Ended		3 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Oct. 31, 2014
	State of West Virginia vs Cardinal Health, Inc	Department of Justice vs Cardinal Health, Inc	CVS Caremark Corporation Member	Scenario, Forecast
				CVS Caremark Corporation Member
Red Oak Sourcing Establishment Date	'	'	'July 2014	'
Red Oak Sourcing Initial Term	'	'	'10 years	'
Number Of Quarterly Payments To CVS	'	'	'	39
Quarterly Payment To CVS	'	'	'	$25.60
Quarterly Payment To CVS Commencement Date	'	'	'	'October 2014
Loss Contingencies	'	'	'	'
Loss Contingency, Number of Defendants	13	'	'	'
Estimated Litigation Liability	'	$27	'	'

Fair_Value_Measurements_Fair_V

Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) (USD $)	Sep. 30, 2014		Jun. 30, 2014
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash equivalents	$309	[1]	$740	[1]
Forward contracts	5	[2]	10	[2]
Available-for-sale securities	91	[3]	100	[3]
Other investments	108	[4]	106	[4]
Total	513		956
Fair Value, Inputs, Level 1	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash equivalents	309	[1]	740	[1]
Forward contracts	0	[2]	0	[2]
Available-for-sale securities	0	[3]	0	[3]
Other investments	108	[4]	106	[4]
Total	417		846
Fair Value, Inputs, Level 2	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash equivalents	0	[1]	0	[1]
Forward contracts	5	[2]	10	[2]
Available-for-sale securities	91	[3]	100	[3]
Other investments	0	[4]	0	[4]
Total	96		110
Fair Value, Inputs, Level 3	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash equivalents	0	[1]	0	[1]
Forward contracts	0	[2]	0	[2]
Available-for-sale securities	0	[3]	0	[3]
Other investments	0	[4]	0	[4]
Total	$0		$0
[1]	Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.
[2]	The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets.
[3]	We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities.
[4]	The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

Financial_Instruments_Narrativ

Financial Instruments (Narrative) (Details) (Designated as Hedging Instrument, Cash Flow Hedging, Interest Rate Swap, USD $)	Sep. 30, 2014
In Millions, unless otherwise specified
Designated as Hedging Instrument | Cash Flow Hedging | Interest Rate Swap	'
Derivative [Line Items]	'
Derivative, Notional Amount	$50

Financial_Instruments_Summary_

Financial Instruments (Summary of Estimated Fair Value of Our Long-Term Obligations and Other Short-Term Borrowings) (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying amount	$4,007	$3,972
Fair Value, Inputs, Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Estimated fair value	$4,122	$4,115

Shareholders_Equity_Narrative_

Shareholders' Equity (Narrative) (Details) (Treasury Shares, USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Treasury Shares	'	'
Treasury shares acquired (using Cost Method), Shares	4.8	1
Treasury shares acquired (using Cost Method), Value	$360	$50
Treasury Stock Acquired, Average Cost Per Share	$74.36	$51.65

Shareholders_Equity_Schedule_o

Shareholders' Equity (Schedule of the changes in the balance in accumulated other comprehensive income by component and in total) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Rollforward]	'	'
Accumulated other comprehensive income at Beginning of Period	$70	'
Other comprehensive loss, net of tax before reclassifications	-24	'
Amounts reclassified to earnings	0	'
Other comprehensive loss, Foreign currency transaction and translation adjustment, Net of tax	-24	24
Other comprehensive loss, Derivatives qualifying as hedges, Net of tax	0	0
Total other comprehensive loss, net of tax	-24	24
Accumulated other comprehensive income at End of Period	46	'
Foreign Currency Translation Adjustments	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Rollforward]	'	'
Accumulated other comprehensive income at Beginning of Period	63	'
Other comprehensive loss, net of tax before reclassifications	-24	'
Amounts reclassified to earnings	0	'
Other comprehensive loss, Foreign currency transaction and translation adjustment, Net of tax	-24	'
Accumulated other comprehensive income at End of Period	39	'
Unrealized Gain/(Loss) on Derivatives, net of tax	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Rollforward]	'	'
Accumulated other comprehensive income at Beginning of Period	7	'
Other comprehensive loss, net of tax before reclassifications	0	'
Amounts reclassified to earnings	0	'
Other comprehensive loss, Derivatives qualifying as hedges, Net of tax	0	'
Accumulated other comprehensive income at End of Period	$7	'

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Details)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'
Potentially dilutive employee stock options, restricted share units and performance share units that were anitdilutive	1	1

Earnings_Per_Share_Reconciliat

Earnings Per Share (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'
Weighted-average common shares-basic	336	340
Effect of dilutive securities:	'	'
Employee stock options, restricted share units and performance share units	4	4
Weighted-average common shares-diluted	340	344

Segment_Information_Narrative_

Segment Information (Narrative) (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
Segment Reporting [Abstract]	'	'	'
Number of Operating Segments	2	'	2
Number of Reportable Segments	2	'	2
Project Costs On Investment And Other Spending	$2	$3	'

Segment_Information_Revenue_by

Segment Information (Revenue by Reportable Segment) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013
Segment Reporting Information	'		'
Revenue	$24,070		$24,523
Pharmaceutical	'		'
Segment Reporting Information	'		'
Revenue	21,209	[1]	21,813	[1]
Medical	'		'
Segment Reporting Information	'		'
Revenue	2,852		2,711
Reportable Segments	'		'
Segment Reporting Information	'		'
Revenue	24,061		24,524
Corporate	'		'
Segment Reporting Information	'		'
Revenue	$9	[2]	($1)	[2]
Walgreen Co | Pharmaceutical	'		'
Segment Reporting Information	'		'
Contract expiration date	'		31-Aug-13
[1]	Our pharmaceutical distribution contract with Walgreen Co. expired on AugustB 31, 2013.
[2]	Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment_Information_Segment_Pr

Segment Information (Segment Profit by Reportable Segment) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Operating earnings	$466	$471
Pharmaceutical	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Operating earnings	451	433
Medical	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Operating earnings	113	106
Reportable Segments	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Operating earnings	564	539
Corporate	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Operating earnings	($98)	($68)

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award	'	'
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$9	$9
Stock Options	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, in years	'3 years	'
Total compensation cost, net of estimated forfeitures, related to unvested awards not yet recognized, pre-tax	39	'
Weighted-average period over which award cost is expected to be recognized (in years)	'2 years	'
Stock Options | Minimum	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'
Exercisable period of plans, in years	'7 years	'
Stock Options | Maximum	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'
Exercisable period of plans, in years	'10 years	'
Restricted Share Units	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, in years	'3 years	'
Total compensation cost, net of estimated forfeitures, related to unvested awards not yet recognized, pre-tax	128	'
Weighted-average period over which award cost is expected to be recognized (in years)	'2 years	'
Performance Share Units	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, in years	'3 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	120.00%	'
Total compensation cost, net of estimated forfeitures, related to unvested awards not yet recognized, pre-tax	$24	'
Performance Share Units | Minimum	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	0.00%	'
Performance Share Units | Maximum	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	200.00%	'

ShareBased_Compensation_Schedu

Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Share-based compensation expense	$25	$24
Restricted Share Units	'	'
Share-based compensation expense	16	16
Stock Options	'	'
Share-based compensation expense	5	5
Performance Share Units	'	'
Share-based compensation expense	$4	$3

ShareBased_Compensation_Schedu1

Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Stock Options Outstanding at Beginning of Period	10
Stock Options Outstanding, Granted	1
Stock Options Outstanding, Exercised	-2
Stock Options Outstanding, Canceled and forfeited	0
Stock Options Outstanding at End of Period	9
Stock Options Outstanding, Exercisable at End of Period	6
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted-Average Exercise Price [Roll Forward]	'
Weighted-Average Exercise Price Per Common Share, Outstanding at June 30, 2014	$39.16
Weighted-Average Exercise Price Per Common Share, Granted	$71.52
Weighted-Average Exercise Price Per Common Share, Exercised	$39.25
Weighted-Average Exercise Price Per Common Share, Canceled and forfeited	$0
Weighted-Average Exercise Price Per Common Share, Outstanding at September 30, 2014	$44.16
Weighted-Average Exercise Price Per Common Share, Exercisable at September 30, 2014	$36.01

ShareBased_Compensation_Schedu2

Share-Based Compensation (Schedule of Additional Data Related to Stock Option Activity) (Details) (Stock Options, USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014
Stock Options	'	'
Aggregate intrinsic value of outstanding options at period end, Stock Options	$282	$282
Aggregate intrinsic value of exercisable options at period end, Stock Options	$219	$185
Weighted-average remaining contractual life of outstanding options	'6 years	'6 years
Weighted-average remaining contractual life of exercisable options	'5 years	'4 years

ShareBased_Compensation_Schedu3

Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) (Restricted Share Units, USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014
Restricted Share Units	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'
Nonvested at Beginning of Period	3
Granted	1
Vested	-1
Canceled and forfeited	0
Nonvested at End of Period	3
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Grant Date Fair Value [Roll Forward]	'
Weighted-Average Grant Date Fair Value Per Share, Nonvested at Beginning of Period	$45.65
Weighted-Average Grant Date Fair Value Per Share, Granted	$71.71
Weighted-Average Grant Date Fair Value Per Share, Vested	$44.34
Weighted-Average Grant Date Fair Value Per Share, Canceled and forfeited	$0
Weighted-Average Grant Date Fair Value Per Share, Nonvested at End of Period	$56.48

ShareBased_Compensation_Schedu4

Share-Based Compensation (Schedule of all Transactions Related to Performance Share Units Under the Plans) (Details) (Performance Share Units, USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014
Performance Share Units	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	120.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'
Nonvested at Beginning of Period	0.9
Granted	0.2
Vested	-0.2	[1]
Canceled and forfeited	0
Nonvested at End of Period	0.9
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Grant Date Fair Value [Roll Forward]	'
Weighted-Average Grant Date Fair Value Per Share, Nonvested at Beginning of Period	$44.41
Weighted-Average Grant Date Fair Value Per Share, Granted	$66.67
Weighted-Average Grant Date Fair Value Per Share, Vested	$41.59
Weighted-Average Grant Date Fair Value Per Share, Canceled and forfeited	$0
Weighted-Average Grant Date Fair Value Per Share, Nonvested at End of Period	$50.51
[1]	Vested based on achievement of 120 percent of the target performance goal.

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)	1 Months Ended		1 Months Ended
In Millions, except Per Share data, unless otherwise specified	Nov. 03, 2014	Oct. 01, 2014	Oct. 31, 2014
	Committed Receivables Sales Facility Program	Committed Receivables Sales Facility Program	Treasury Shares
Subsequent Event	'	'	'
Treasury shares acquired (using Cost Method), Shares	'	'	3.1
Treasury shares acquired (using Cost Method), Value	'	'	$231
Treasury Stock Acquired, Average Cost Per Share	'	'	$74.12
Line of credit facility, effective date of increase	3-Nov-14	'	'
Line of Credit Facility, Expiration Date	3-Nov-17	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$950	$700	'